Netland P A, Chaturvedi N, Dreyer E B
Glaucoma Service, Massachusetts Eye and Ear Infirmary, Boston 02114.
Am J Ophthalmol. 1993 May 15;115(5):608-13. doi: 10.1016/s0002-9394(14)71458-8.
Fifty-six patients with either open-angle or low-tension glaucoma who were concurrently taking calcium channel blockers were compared to similar groups not taking such medications for a mean follow-up period of 3.4 years. Serial stereoscopic optic nerve photographs and visual fields of all patients were evaluated for evidence of glaucomatous progression. In patients with low-tension glaucoma, there was a significant difference in the progression of visual field defects, with only two of 18 eyes (11%) of patients taking calcium channel blockers, compared to ten of 18 eyes (56%) of controls showing new visual field defects. Similarly, low-tension glaucoma patients taking calcium channel blocker therapy demonstrated no evidence of progressive optic nerve damage, compared to eight of 18 control eyes (44%). In contrast, patients with open-angle glaucoma taking calcium channel blockers showed no marked difference in the progression of glaucoma, compared to controls. These findings suggest that calcium channel blockers may be useful in the management of low-tension glaucoma.
56例同时服用钙通道阻滞剂的开角型或低眼压性青光眼患者与未服用此类药物的相似组进行比较，平均随访期为3.4年。对所有患者的系列立体视盘照片和视野进行评估，以寻找青光眼进展的证据。在低眼压性青光眼患者中，视野缺损进展存在显著差异，服用钙通道阻滞剂的患者18只眼中仅有2只（11%）出现新的视野缺损，而对照组18只眼中有10只（56%）出现新的视野缺损。同样，服用钙通道阻滞剂治疗的低眼压性青光眼患者未显示出视神经进行性损害的证据，而对照组18只眼中有8只（44%）出现视神经进行性损害。相比之下，服用钙通道阻滞剂的开角型青光眼患者与对照组相比，青光眼进展无明显差异。这些发现表明钙通道阻滞剂可能有助于低眼压性青光眼的治疗。
